WebIrinotecan hydrochloride trihydrate, CPT -11 COMMON TRADE NAME(S): CAMPTOSAR® CLASSIFICATION: Topoisomerase I inhibitor. Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM OF ACTION: Irinotecan is a semisynthetic, water -soluble derivative of camptothecin, which is a cytotoxic alkaloid ... WebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly of gastrointestinal origin. Dysarthria secondary to irinotecan has been described as a rare side effect in a few case reports with limited data to recommend appropriate …
DRUG NAME Irinotecan - BC Cancer
WebTrade Name: CAMPTOSAR; CAMPTO Chemical Family: Mixture Intended Use: Pharmaceutical product used as Antineoplastic 2. HAZARDS IDENTIFICATION ... Irinotecan Hydrochloride 100286-90-6 Not Listed Mut. Cat.3;R68 Repr. Cat.3;R61 Xn;R22 2% Sodium hydroxide 1310-73-2 215-185-5 C;R35 ** WebClick on the irinotecan (Camptosar) package insert link below for a complete list of reported side effects and possible drug interactions; Side Effect Videos Nausea and Vomiting Diarrhea Hair Loss Fatigue Pain Neutropenic Fever Blood Clots See DailyMed package insert. Share this page: flowering mango tree
Reimbursement Policy Camptosar (Irinotecan) - AAPC
WebIrinotecan (Camptosar) patient drug information (UpToDate) [4] History of changes in FDA indication 6/14/1996: Initial accelerated approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5 … WebActive ingredient: irinotecan hydrochloride trihydrate. The concentrate contains 20 mg/ml irinotecan hydrochloride trihydrate (equivalent to 17.33 mg/ml irinotecan). Excipients: sorbitol, lactic acid and water for injections. The pH of the solution is adjusted to 3.5 with sodium hydroxide. WebThe CAMPTOSAR (irinotecan) package insert recommends a reduced initial dose be considered for patients homozygous for the UGT1A1*28 allele and are at an increased risk for neutropenia following initiation of CAMPTOSAR treatment. AutoGenomics Doc EM-34028E (English) Rev. I (CO 4027) May 2024 greenacre nursery bootle